ONCAlert | 2018 ASCO Annual Meeting
Conference  >  ASH CLL Spotlight  >  

An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

Nitin Jain, MD
Published Online: 11:28 PM, Mon December 5, 2016

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.